Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In ...

An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...

If you are wondering whether Travere Therapeutics at around US$38.78 is offering value or asking too much, this breakdown is designed to help you make sense of the current price. The stock has been ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price ...

Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...

The Summers Value Fund LP returned 6.7% net in 2025, trailing Russell 2000 Index ETF, which returned 12.7%, and Russell 2000 ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Ardelyx, with a price target of $16.00.

"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...

AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

RYAN JOINS ANOTHER BOARD: Former Speaker Paul Ryan is joining the strategic advisory board for defense tech startup ...